news

Our latest
Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI is proud to have provided its CE-marked AI tools for fluid quantification to support the analysis in a large scale, multicenter, real-world national database of neovascular Age related Macular Degeneration (nAMD) patients. The results of the study, recently published in the British Journal of Ophthalmology, demonstrate that volumetric measures derived from AI-based segmentation of OCT volumes provide useful information for clinicians to consult their patients at diagnosis.

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI is proud to launch Discovery CORE™ with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently, in real time, with their peers, on medical and imaging datasets. Automatically and in an instant, the software measures retinal fluid volumes and retinal layer thickness across OCT datasets. With built-in annotation tools and electronic case report forms, new data insights can also be collected across peer networks, keeping the information digitized, centralized and secure.

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI is a leader in clinical and imaging data management software and advanced analytics for Ophthalmology. The company’s platform technology and AI improve workflows in research, clinical studies and bring precision medicine applications to pharma, clinical research organizations (CROs) and clinicians.

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

RetinAI, a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.

124E International Congress de la SFO [MAY'18]

RetinAI had the pleasure to present in the 124e Congrès International de la Société Française d'Ophthalmologie in the session: 'L'impact de l'intelligence artificielle dans la santé visuelle', organised by Optic 2000 in Paris! Wonderful day presenting how AI and machine learning are changing the current paradigm of screening and monitoring of eye diseases.

‍

ARVO 2018 Honolulu - Hawaï [APRIL-MAY'18]

RetinAI is getting ready for the American Research in Vision and Ophthalmology #ARVO2018 in Hawaii! Come to our booth 1039 if you want to learn about how #AI is changing the world of ophthalmic care!

Bilan Magazine TOP 50 Startups in which to invest 2018 [FEBRUARY'18]

RetinAI has been selected as one of the TOP50 Swiss startups in which to invest by the Bilan Magazine. The committee of experts evaluated the progress and projection of hundreds of startups from the Swiss ecosystem and selected the 50 most promising technologies for 2018! Congratulations to the team for this great success.

Read more

‍

5th international Congress OCT Angiography [DECEMBER'17]

RetinAI will be presenting the latest company's developments in this year's edition of the 5th International Congress on OCT Angiography in Rome, on the 15-16th December. Don't forget to come to our session: Unleashing the potential of longitudinal image analysis in Optical Coherence Tomography.

Our latest
Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

Latest updates

124E International Congress de la SFO [MAY'18]

ARVO 2018 Honolulu - Hawaï [APRIL-MAY'18]

Bilan Magazine TOP 50 Startups in which to invest 2018 [FEBRUARY'18]

5th international Congress OCT Angiography [DECEMBER'17]

Contact us for more informations! We are happy to hear from you!

Sign Up And Receive Our Latest Promotions!

Our latest Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

Latest updates

124E International Congress de la SFO [MAY'18]

ARVO 2018 Honolulu - Hawaï [APRIL-MAY'18]

Bilan Magazine TOP 50 Startups in which to invest 2018 [FEBRUARY'18]

5th international Congress OCT Angiography [DECEMBER'17]

Contact us for more informations! We are happy to hear from you!

Our latest
Press Releases & Updates